ISPOR - EE474 Cost-Effectiveness Model for a Novel Functional ASSAY Versus Provider Selection of Third-Line Treatment of Patients with Refractory Metastatic Colorectal Cancer

EE474 Cost-Effectiveness Model for a Novel Functional ASSAY Versus Provider Selection of Third-Line Treatment of Patients with Refractory Metastatic Colorectal Cancer

Abstract

Authors

N Oh D Hsu S Skrzypczak G Lopes

Full Text Cite This Article

Back to Volume 25, Supplemental Issue 7S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now